A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

132

Participants

Timeline

Start Date

November 8, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions

Neoplasm Malignant

Interventions

BIOLOGICAL

STRO-002

STRO-002 is an Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs.

Trial Locations (1)

RECRUITING

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors

collaborator

Sutro Biopharma, Inc.

INDUSTRY

lead

Tasly Pharmaceutical Group Co., Ltd

INDUSTRY